MGMT and glioblastoma: According to the combination of patient age, MGMT, and BICD1 expression, GBM patients who received TMZ treatment could be further separated into more distinct risk groups, which may provide more predictive information of patients’ outcomes, and help neuro-oncologists make better individualized therapeutic decisions, and develop personalized therapy or precision medicine for GBM patients in the future.